These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 27190359)

  • 1. Pro: Cyclophosphamide in lupus nephritis.
    Kallenberg CG
    Nephrol Dial Transplant; 2016 Jul; 31(7):1047-52. PubMed ID: 27190359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Con: Cyclophosphamide for the treatment of lupus nephritis.
    Mok CC
    Nephrol Dial Transplant; 2016 Jul; 31(7):1053-7. PubMed ID: 27190358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Moderator's view: Cyclophosphamide in lupus nephritis.
    Tesar V
    Nephrol Dial Transplant; 2016 Jul; 31(7):1058-61. PubMed ID: 27190357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maintenance therapies for proliferative lupus nephritis: mycophenolate mofetil, azathioprine and intravenous cyclophosphamide.
    Contreras G; Tozman E; Nahar N; Metz D
    Lupus; 2005; 14 Suppl 1():s33-8. PubMed ID: 15803929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclophosphamide treatment in systemic necrotizing vasculitis and lupus nephritis. How long? How much?
    Beimler JH; Andrassy K
    Pediatr Nephrol; 2004 Sep; 19(9):949-55. PubMed ID: 15257454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What is the value of mycophenolate mofetil as induction and maintenance therapy in lupus nephritis?
    Jones RB; Walsh M; Smith KG
    Curr Opin Rheumatol; 2009 May; 21(3):256-61. PubMed ID: 19399995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of low-dose cyclophosphamide followed by AZA/MMF treatment in childhood lupus nephritis.
    Baskin E; Ozen S; Cakar N; Bayrakci US; Demirkaya E; Bakkaloglu A
    Pediatr Nephrol; 2010 Jan; 25(1):111-7. PubMed ID: 19727839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mycophenolate mofetil for lupus nephritis: an update.
    Mok CC
    Expert Rev Clin Immunol; 2015; 11(12):1353-64. PubMed ID: 26364748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Could we abandon cyclophosphamide in systemic vasculitis and lupus nephritis?
    Kallenberg CG
    Ann Rheum Dis; 2013 Apr; 72 Suppl 2():ii62-5. PubMed ID: 23253917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pro: The use of calcineurin inhibitors in the treatment of lupus nephritis.
    Mok CC
    Nephrol Dial Transplant; 2016 Oct; 31(10):1561-6. PubMed ID: 27591327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis.
    Chan TM; Tse KC; Tang CS; Mok MY; Li FK;
    J Am Soc Nephrol; 2005 Apr; 16(4):1076-84. PubMed ID: 15728784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide.
    Houssiau FA; Vasconcelos C; D'Cruz D; Sebastiani GD; Garrido Ed Ede R; Danieli MG; Abramovicz D; Blockmans D; Mathieu A; Direskeneli H; Galeazzi M; Gül A; Levy Y; Petera P; Popovic R; Petrovic R; Sinico RA; Cattaneo R; Font J; Depresseux G; Cosyns JP; Cervera R
    Arthritis Rheum; 2002 Aug; 46(8):2121-31. PubMed ID: 12209517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative efficacy and safety of tacrolimus, mycophenolate mofetil, azathioprine, and cyclophosphamide as maintenance therapy for lupus nephritis : A Bayesian network meta-analysis of randomized controlled trials.
    Lee YH; Song GG
    Z Rheumatol; 2017 Dec; 76(10):904-912. PubMed ID: 27638015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lupus nephritis: maintenance therapy for lupus nephritis--do we now have a plan?
    Lenz O; Waheed AA; Baig A; Pop A; Contreras G
    Clin J Am Soc Nephrol; 2013 Jan; 8(1):162-71. PubMed ID: 22917704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Mycophenolate Mofetil Versus Intravenous Pulse Cyclophosphamide as Induction Therapy in Proliferative Lupus Nephritis.
    Gadakchi L; Hajialilo M; Nakhjavani MR; Abedi Azar S; Kolahi S; Gojazadeh M; Ebrahimi AA; Malek Mahdavi A; Noshad H; Khabbazi A
    Iran J Kidney Dis; 2018 Oct; 12(5):288-292. PubMed ID: 30367020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequential therapies for proliferative lupus nephritis.
    Contreras G; Pardo V; Leclercq B; Lenz O; Tozman E; O'Nan P; Roth D
    N Engl J Med; 2004 Mar; 350(10):971-80. PubMed ID: 14999109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mycophenolate mofetil versus azathioprine in the maintenance therapy of lupus nephritis.
    Sahin GM; Sahin S; Kiziltas S; Masatlioglu S; Oguz F; Ergin H
    Ren Fail; 2008; 30(9):865-9. PubMed ID: 18925525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of low-dose intravenous cyclophosphamide with oral mycophenolate mofetil in the treatment of lupus nephritis.
    Rathi M; Goyal A; Jaryal A; Sharma A; Gupta PK; Ramachandran R; Kumar V; Kohli HS; Sakhuja V; Jha V; Gupta KL
    Kidney Int; 2016 Jan; 89(1):235-42. PubMed ID: 26489028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is mycophenolate mofetil superior to pulse intravenous cyclophosphamide for induction therapy of proliferative lupus nephritis in Egyptian patients?
    El-Shafey EM; Abdou SH; Shareef MM
    Clin Exp Nephrol; 2010 Jun; 14(3):214-21. PubMed ID: 20169461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lupus nephritis: induction therapy in severe lupus nephritis--should MMF be considered the drug of choice?
    Rovin BH; Parikh SV; Hebert LA; Chan TM; Mok CC; Ginzler EM; Hooi LS; Brunetta P; Maciuca R; Solomons N
    Clin J Am Soc Nephrol; 2013 Jan; 8(1):147-53. PubMed ID: 22879439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.